Systemic therapies in the treatment of non-small-cell lung cancer brain metastases

Rimas V. Lukas*, Priya Kumthekar, Syeda Rizvi, Ravi Salgia

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Non-small-cell lung cancer (NSCLC) brain metastases are common. Even though there are various subsets of NSCLC with molecular alterations, there is a common theme of brain metastases. Current treatment modalities are suboptimal. Systemic therapies for the treatment of NSCLC brain metastases have been explored and recent advances may pave the way for their successful employment in this patient population. While no specific agents have been associated with a marked benefit, stability of disease as well as radiographic responses have been noted in some patients. Biological activity of systemic therapies in some patients with NSCLC brain metastases raises hope for future advances and supports further investigation for this patient population with limited treatment options.

Original languageEnglish (US)
Pages (from-to)1045-1058
Number of pages14
JournalFuture Oncology
Issue number8
StatePublished - Apr 2016


  • antiangiogenics
  • brain metastases
  • chemotherapy
  • immunotherapy
  • metastases
  • neoplasm
  • non-small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Systemic therapies in the treatment of non-small-cell lung cancer brain metastases'. Together they form a unique fingerprint.

Cite this